Physician profile
Anna Tobin
NPI 1033735709
$1,436.13
in general payments reported to CMS, 2019-2025
18 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $167 · 2024: $594 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.43 | 2023-2025 | |
| Novo Nordisk INC | $270.02 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Supernus Pharmaceuticals, INC. | $121.38 | 2024 | Qelbree |
| Lilly USA, LLC | $117.99 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $74.75 | 2025 | Veozah |
| Pfizer INC. | $60.75 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $52.12 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $44.15 | 2024-2025 | Breztri |
| Alvogen INC | $38.11 | 2023-2024 | Teriparatide |
| Exact Sciences Corporation | $37.75 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $29.38 | 2025 | |
| Collegium Pharmaceutical, INC. | $23.27 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $19.73 | 2025 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $18.96 | 2024 | Quviviq |
| Axsome Therapeutics, INC. | $18.14 | 2024 | Sunosi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $17.78 | 2025 | Xelstrym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.71 | 2024 | Caplyta |
| Medtronic, INC. | $13.71 | 2025 | Inceptiv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.